12 results about "Plasma concentration" patented technology

The present invention relates to the crystalline form of bipyrimidine compounds, as well as methods for preparing the same and their use. In particular, the present invention relates to crystalline form I of 4'-cyclopropyl-5,6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazole-2-yl)bicyclo[2.2.2]octan-1-yl)methyl)-[2,5'-bipyrimidine]-4-amine, wherein the X-ray powder diffraction pattern of crystalline form I includes characteristic peaks at diffraction angles (2θ) of 6.378±0.2°, 9.521±0.2°, 15.721±0.2°, 16.379±0.2°, 16.981±0.2°, 17.560±0.2°, 19.080±0.2° and 22.200±0.2°. Crystal form I possesses high stability, high solubility, high plasma concentration, high bioavailability, and excellent pharmacological activity, making it suitable for pharmaceutical preparations.

The present invention relates to a syrup containing alectinib or a salt thereof. The present invention provides a syrup containing alectinib or a salt thereof, which is a poorly water soluble agent, and having improved fluidity and / or palatability. The syrup of the present invention has a plasma concentration profile equivalent to or greater than, or is biologically equivalent to, a capsule containing the same amount of alectinib or a salt thereof as the syrup, or has an enhanced oral bioavailability compared to a capsule containing the same amount of alectinib or a salt thereof as the syrup.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / ml after administration of the pharmaceutical composition to a human.

Disclosed herein is a method for predicting whether a subject with cancer will exhibit a beneficial response to arginine deficiency therapy. The method includes the step of determining the plasma concentration of arginine in the subject, followed by administering arginine deficiency therapy to the subject alone or in combination with an anticancer agent, based on the determined plasma concentration of arginine. According to some embodiments of this disclosure, the anticancer agent is selected from the group consisting of FOLFOX, docetaxel, cisplatin, pemetrexed, pembrolizumab, and combinations thereof.

This invention relates to the interdisciplinary field of biomedical detection and Internet of Things (IoT) sensing technology, specifically disclosing a platelet-rich plasma concentration detection system based on IoT biosensors. The system includes a microfluidic sensor chip, a multi-frequency electrochemical impedance spectroscopy (MES) acquisition unit, a cell morphology identification module, an IoT communication unit, and a remote data processing server. It monitors platelet dynamic aggregation in real time through a three-electrode system, and combines high-dimensional features of broadband impedance spectroscopy with a pre-trained convolutional neural network model to accurately distinguish between simple platelet aggregates, platelet-leukocyte complexes, and microthrombus structures. Furthermore, it leverages the IoT architecture to complete encrypted data upload, remote model optimization, and intelligent coagulation risk assessment. Through the above technical solutions, this invention improves the sensitivity, specificity, and clinical applicability of the detection, constructing a closed-loop blood monitoring system from bedside detection to cloud-based decision support.

The present invention provides compositions and related methods for treating interleukin-5 (IL-5) mediated diseases in children. [Solution] A method for treating a disease in a child, comprising the steps of: a) identifying a child weighing less than 40 kg who has a disease selected from the group consisting of asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, poorly controlled eosinophilic asthma, etc.; and b) subcutaneously administering a therapeutically effective dose of mepolizumab to the child, wherein the therapeutically effective dose of the antibody results in a maximum plasma concentration (Cmax) of antibody of approximately 10.1960 ± 0.3345 μg / mL and an area under the curve [0-infinity] value of approximately 454.39 ± 15.8876 μg* / mL, thereby treating the disease in the child.

Disclosed are a gastroretentive double-layer sustained-release tablet, a preparation method therefor, and use thereof. An active ingredient of the gastroretentive double-layer sustained-release tablet is 3-[4-[4-(lH-benzotriazol-1-yl)butyl]piperazin-1-yl]benzisothiazole hydrochloride. Said tablet consists of two drug release layers comprising an immediate-release layer and a sustained-release layer. The immediate-release layer comprises the active ingredient, a filler I, and a disintegrant, and the sustained-release layer comprises the active ingredient, a filler II, a swelling material, a release blocker, a swelling enhancer, and a stabilizer. Said tablet can prolong the in vivo absorption window of the drug, maintain the plasma concentration, and prolong the in vivo half-life of the active ingredient.

An oral dosage form of an antidiabetic pharmaceutical composition comprises a core portion, an outer portion, and a controlled membrane film sandwiched therebetween. The core portion comprises metformin and a release-preventing agent. The controlled membrane film is provided with at least one passageway. The outer portion comprises a non-biguanide antidiabetic agent. In the oral dosage form, the metformin has a dissolution profile such that upon dissolving in a medium with a pH of approximately 6.8 at approximately 37° C., less than 15% is released from the oral dosage form at 2 hours, approximately 60-70% is released at 12 hours, and more than 80% is released at 20 hours. Upon a single-dose oral administration, the time that the oral dosage form provides a maximum plasma concentration of the metformin in a subject is from approximately 8 to 20 hours after administration.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / mL after administration of the pharmaceutical composition to a human.

This invention discloses a method for quantitatively detecting sunitinib (SUN) and N-deethylsunitinib (SU12662) in dried blood spots and its application. This invention employs quantitative dried blood spot (qDBS) sampling combined with LC-MS / MS detection. By using fixed-volume sample loading and whole-spot sampling, hematocrit interference is eliminated. Under specific chromatographic and mass spectrometric conditions, precise quantification of SUN and SU12662 in dried blood spots is achieved. Simultaneously, this invention establishes a dried blood spot-plasma concentration conversion model, converting whole blood concentrations to clinically applicable plasma concentrations, forming a home sampling protocol for sunitinib treatment monitoring. This method requires only 15 μL of fingertip blood, the sample is stable and easy to store and transport, exhibits good linearity, high sensitivity, and minimal matrix effect, and can tolerate 30%–50% hematocrit fluctuations. It allows for home self-collection, is non-invasive and convenient, and the results are highly consistent with clinical venous blood collection, effectively improving patient compliance and accessibility to treatment monitoring. It is suitable for personalized sunitinib medication guidance.

The application discloses a low-temperature plasma concentration soft measurement method and device based on emission spectrum, and the method comprises the following steps: a soft measurement model establishing and calibrating stage, a soft measurement model correction stage under general working conditions, and a model actual application and calibration stage; data is collected by a mass spectrometer and a spectrometer and is pretreated, the pretreated data is used for training a partial least square model with dimension reduction capacity, the model is corrected based on an instrument sampling mechanism, and finally the soft measurement model is applied to a general reactor by means of a method for calibrating the model by using inert gas.

The present disclosure provides methods of treating a disease or disorder in a patient comprising administering 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione (“Compound (1)”), or a pharmaceutically acceptable salt thereof, to the patient, wherein the patient achieves a threshold steady-state plasma concentration of Compound (1). The present disclosure also provides methods of administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, to a patient. Compound (1) is a PPAR-γ agonist that is used to treat a variety of diseases and disorders including, but not limited to, nonalcoholic steatohepatitis and central nervous system diseases, e.g., X-linked adrenoleukodystrophy, Friedreich's Ataxia.